**4. Conclusions**

The assessment of pharmaceutical drugs and healthcare programs has been in recent years expanded beyond efficacy and safety to cover economic implications and other consequences. The incorporation of an economic perspective into the decision making process as to which therapies will be reimbursed by the national healthcare system and not only that, has made the subject of debate and discussion. National programs combining patient education with behavioral intervention strategies could decrease the financial losses due to poor adherence. The intention of this chapter was to highlight a very important problem of adherence in direct symbiosis with the economic situation. To ascertain the true extent of financial losses due to low adherence in emerging countries, more studies are urgently required. The absence of national policies grows the financial losses due to poor adherence. The answer, in our opinion, is not to spend more money on drugs and expensive treatment costs, but to work towards the patient in general. As individuals we are constantly making choices as to how we use our time and money, but we do not always think about our wellbeing regarding the health.
